Form FDA 483 · Issued 2025-10-24
Inotiv Inc. — FDA Form 483 Analysis
FEI: 1000140135 · Sector: Pharmaceuticals & Sterile/OTC Drugs (Biopharmaceutics Analytical Facility & Nonclinical Laboratory) · Lead Investigator: Priya N. Subramanian
FDA Form 483 issued to Inotiv Inc. (FEI 1000140135) on 2025-10-24 following an inspection of its biopharmaceutics analytical facility & nonclinical laboratory operations in United States. The report documents 2 inspection observations centered on Master Manufacturing & Batch Production Records (MMR/BPR), Finished Product Testing, Stability & Expiration Dating.
Get Full Annotated 483 Dossier + CAPA Checklist
Instant PDF + CFR Matrix ($79 vs. Redica's $289)
Need Help Fixing These 2 Citations?
Get matched with a vetted 21 CFR remediation consultant
Observation-by-Observation 21 CFR Breakdown (2)
Observation #1 · 21 CFR 211.188(b)(13)
Master Manufacturing & Batch Production Records (MMR/BPR)
FIRST-TIME OBSERVATION
Results of drug product inspections and examinations
Inspector Observation Language: "The batch production and control records are deficient in that they do not include results of drug product [examinations] [inspections]. Specifically, observed during inspection of Inotiv Inc. on 2025-10-24."
Plain-English Meaning: Missing Master Manufacturing Records (MMRs) or incomplete Batch Production Records (BPRs) lacking exact component weights, lot numbers, yield reconciliation, or second-person verification.
Standard CAPA Remediation Path: Ensure every product SKU has an approved MMR matching the exact label claim and every batch record captures raw material lot traceability, in-process weight/pH checks, and QA release signatures.
Observation #2 · 21 CFR 211.194(a)(8)
Finished Product Testing, Stability & Expiration Dating
FIRST-TIME OBSERVATION
Identification of Person Performing Review of Lab Records
Inspector Observation Language: "Laboratory records are deficient in that they do not include the [initials] [signature] of the second person reviewing the record for accuracy. Specifically, observed during inspection of Inotiv Inc. on 2025-10-24."
Plain-English Meaning: Releasing finished batches without verifying strength/potency/microbiological specs, or placing an expiration/best-by date on labels without supporting real-time or accelerated stability data.
Standard CAPA Remediation Path: Require finished-batch microbiological (USP <2021>/<2022>), heavy metal, and active-assay release testing plus ICH stability chamber protocols supporting every label shelf-life claim.